Background: Changes in revascularization strategies and outcomes among patients with significant unprotected left main coronary artery (LMCA) stenosis remain largely unknown. Methods: A total of 2618 consecutive patients with LMCA stenosis undergoing revascularization treatment between 1995 and 2010 were identified from ASAN MAIN registry. Patients were classified into three periods: bare metal stent (WAVE1) period (1995)(1996)(1997)(1998), early drug-eluting stent (WAVE2) period (2003)(2004)(2005)(2006), and late drug-eluting stents (WAVE3)period (2007)(2008)(2009)(2010). The major adverse cerebro-cardiovascular events (MACCE) were defined as death, myocardial infarction, repeat revascularization, or stroke at 2-years. Results: The major adverse cerebro-cardiovascular events (MACCE) were defined as death, myocardial infarction, repeat revascularization, or stroke at 2-years.During study periods, 1124 patients underwent percutaneous coronary intervention (PCI) with stent and 1494 patients underwent coronary artery bypass grafting (CABG). The proportion of PCI significantly increased from 35% to 52%. Among patients receiving PCI, the risk-adjusted incidence rate of MACCE decreased from 20.18 cases per 100 person-years in WAVE1 to 6.77 cases per 100 person-years in WAVE3 (P< 0.001 for trend). Death, the composite of death, myocardial infarction, or stroke, and repeat revascularization were also significantly decreased by 40%, 35%, and 46%, respectively. However, among patients receiving CABG, the risk-adjusted incidence rate of MACCE was not significantly changed during study period. In addition, the difference in the risk of MACCE between PCI and CABG progressively reduced (adjusted hazard ratio Background: The aim of this study was to assess efficacy and safety profile of distal LM stenosis treatment with dedicated bifurcation BiOSS stents (Balton, Poland): in group I -paclitaxel-eluting BiOSS ExpertÒ and in group II -sirolimus-eluting BiOSS LIMÒ. Methods: Patients with CAD or NSTE-ACS were enrolled between January 2011 and June 2013 in three centers in Bulgaria, Poland and Spain. Decision for LM stenting was based on Heart Team consensus. Provisional T-stenting was default strategy. Control angiography was planned at 12 months in all patients. The primary end point is MACE at 12 months. Here, we present 6-month clinical data from both groups and completed angiographic data from BiOSS Expert. At the time of TCT 2014 angiographic data from BiOSS LIM will be completed. Results: There were enrolled 158 patients (62 in BiOSS Expert group and 96 in BiOSS LIM group). The average age was 65.7AE12.5 yrs and 19.7% were female. In the study 17.8% of patients were with NSTE-ACS, 73.4% with hypertension, 81.4% with dyslipidemia, 32.1% with diabetes, 39.2% with prior MI, 43.3% with prior PCI and 17.4% with prior CABG. The mean SYNTAX score was 21.52AE6.58. True bifurcations were treated in 70.1% of cases. All BiOSSÒ stents were implanted successfully. The nominal stent parameters were as followed: BiOSS Expert group: 4.07AE0.26mm (proximal diameter) x 3.36AE0.26mm (distal diameter) x 16.61AE1.72 mm (length) and BiOSS LIM group: 3.90AE0.4mm x 3.17AE0.39mm x 16.81AE2.06mm. Classical DES in side branch was implanted in 25.9% and 21.4%, respectively. Almost 62% of procedures were done from radial access and 83% with 6F catheter. After 12 months in BiOSS Expert group angiographically-driven TLR rate was 9.6%, whereas clinically-driven TLR was 3.2%. In BiOSS LIM group data are pending -at 6 months there were no death or MI. In BiOSS Expert group late lumen loss was as follows: in main vessel -0.21AE0.1mm, in main branch -0.26AE0.12mm and in side branch -0.14AE0.09mm. Conclusions: Dedicated bifurcation BiOSS stents seem feasible devices with promising effectiveness and safety profile in distal LM stenosis. Complete BiOSS LIM data facilitate to answer the question if the used drug or stent design is more crucial.
Background: The aim of this study was to assess efficacy and safety profile of distal LM stenosis treatment with dedicated bifurcation BiOSS stents (Balton, Poland): in group I -paclitaxel-eluting BiOSS ExpertÒ and in group II -sirolimus-eluting BiOSS LIMÒ. Methods: Patients with CAD or NSTE-ACS were enrolled between January 2011 and June 2013 in three centers in Bulgaria, Poland and Spain. Decision for LM stenting was based on Heart Team consensus. Provisional T-stenting was default strategy. Control angiography was planned at 12 months in all patients. The primary end point is MACE at 12 months. Here, we present 6-month clinical data from both groups and completed angiographic data from BiOSS Expert. At the time of TCT 2014 angiographic data from BiOSS LIM will be completed. Results: There were enrolled 158 patients (62 in BiOSS Expert group and 96 in BiOSS LIM group). The average age was 65.7AE12.5 yrs and 19.7% were female. In the study 17.8% of patients were with NSTE-ACS, 73.4% with hypertension, 81.4% with dyslipidemia, 32.1% with diabetes, 39.2% with prior MI, 43.3% with prior PCI and 17.4% with prior CABG. The mean SYNTAX score was 21.52AE6.58. True bifurcations were treated in 70.1% of cases. All BiOSSÒ stents were implanted successfully. The nominal stent parameters were as followed: BiOSS Expert group: 4.07AE0.26mm (proximal diameter) x 3.36AE0.26mm (distal diameter) x 16.61AE1.72 mm (length) and BiOSS LIM group: 3.90AE0.4mm x 3.17AE0.39mm x 16.81AE2.06mm. Classical DES in side branch was implanted in 25.9% and 21.4%, respectively. Almost 62% of procedures were done from radial access and 83% with 6F catheter. After 12 months in BiOSS Expert group angiographically-driven TLR rate was 9.6%, whereas clinically-driven TLR was 3.2%. In BiOSS LIM group data are pending -at 6 months there were no death or MI. In BiOSS Expert group late lumen loss was as follows: in main vessel -0.21AE0.1mm, in main branch -0.26AE0.12mm and in side branch -0.14AE0.09mm. Conclusions: Dedicated bifurcation BiOSS stents seem feasible devices with promising effectiveness and safety profile in distal LM stenosis. Complete BiOSS LIM data facilitate to answer the question if the used drug or stent design is more crucial.
TCT-226
Impact Background: Final kissing balloon inflation (FKBI) is a mandatory technique in unprotected left main (ULM) revascularization with 2-stent strategy. However, there is no consensus regarding the necessity of FKBI in single-stent strategy. Therefore, to assess the need of FKBI for single-stent strategy in ULM lesion, we compared clinical outcome between patients treated using single-stent strategy with FKBI and those without FKBI. Methods: A total of 654 consecutive patients who had ULM lesion were treated using drug-eluting stent between April 2005 and August 2010. Of these, 470 patients were eligible in this study after exclusion of 21 patients with ostial ULM and 163 patients treated using 2-stent strategy. In patients using single-stent strategy, 357 patients were proceeded with FKBI (FKBI group) and 113 patients were without FKBI (no-FKBI group). The end point of this study is the occurrence of Major Adverse Cardiovascular Event (MACE) defined as composites of all cause death, target lesion revascularization (TLR) and MI. Furthermore, overall TLR, TLR for main branch (TLR-MB) involving ULM to left anterior descending artery and TLR for side branch alone (TLR-SB) involving left circumflex (LCx) at 1-year were evaluated. Results: Patient and lesion characteristics were similar between the 2 groups. Following single-stent strategy, 36 patients (8.9%) necessitated an additional bailout stenting for ostial LCx stenosis. In the total population, the occurrence of MACE at 1 year is similar between the two groups (7.4% in the FKBI group and 11.9% in the no FKBI group, log rank p¼0.112). The incidences of overall TLR, TLR-MB and TLR-SB at 1 year were also similar between FKBI group vs. no-FKBI group (7.0% vs. 9.3%, p¼0.44, 2.5% vs. 4.7%, p¼0.24 and 5.0% vs.5.6%, p¼0.81, retrospectively). Conclusions: Single-stent for ULM disease was feasible at mid-term follow-up. However, FKBI had no impact on clinical outcome following ULM revascularization with Single-stent strategy.
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Results: Pre-procedural EF was not different between two groups (34.3 AE 5.9 vs. 32.4 AE 6.2%, P¼0.10). The CABG group included more patients with triple-vesseldisease (P< 0.001) and the PCI group included more patients with presenting with myocardial infarction (MI) (P¼0.002). At 2 years, death occurred in 7 (17.1%) of the PCI group and 27 (15.7%) of the CABG group (P¼0.73). Results: There were no statistical differences in MACE and other endpoints between the two groups ( Figure) . A favorable trend for ULMT lesion was shown in MACE (p¼0.09).
Conclusions: DES implantation with single stent strategy for ULMT bifurcation lesion provides as feasible long-term outcome as for LAD lesion. 
